DBV Technologies | Chart & Forecast SummaryKey Indicators On Trade Set Up In General
1. Push Set Up
2. Range Set up
3. Break & Retest Set Up
Notes On Session
# DBV Technologies
- Double Formation
* A+ Set Up | Wedge Structure Template | Subdivision 1
* (3) Wave Short End
- Triple Formation
* Neckline | Left & right At 0.90 |Subdivision 2
*
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−5.87 USD
−113.92 M USD
0.00 USD
27.32 M
About DBV TECHNOLOGIES
Sector
Industry
CEO
Daniel Tassé
Website
Headquarters
Chatillon
Founded
2002
FIGI
BBG0076D3T39
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Chatillon, France.
DBV Technologies SAOn the above bi-weekly chart price action has corrected over 95% since the sell signal (not shown). Now is an excellent long moment. Why?
1) A strong buy signal (not shown).
2) Price action is printing strong bullish divergence, look left.
3) No stock splits.
Is it possible price action falls fu
DBV Technologies rally on Positive FDA CommunicationDBV Technologies Spikes on Positive FDA Communication
DBV Technologies received positive responses from the U.S. Food and Drug Administration regarding its application for a peanut allergy treatment.
The U.S. FDA provided type A meeting requests to the questions the French company submitted in Oct
DBV Technologies Reports H1-20DBV Technologies Reports H1-20
themarketsignal.com
DBV TECHNOLOGIES ADR (NASDAQ:DBVT) is reflecting bullish signals with a RSI of 19.89. The clinical-stage biopharmaceutical company reported financial figures for the H1-20. DBVT reported €225.9 million cash and cash equivalents at the end of H1-20.
DBV Technologies Reports H1-20DBV Technologies Reports H1-20
themarketsignal.com
DBV TECHNOLOGIES ADR (NASDAQ:DBVT) is reflecting bullish signals with a RSI of 19.89. The clinical-stage biopharmaceutical company reported financial figures for the H1-20. DBVT reported €225.9 million cash and cash equivalents at the end of H1-20.
$DBVT Bio Pharm Company is on our watchlist.DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children
DBVT - Fallen angle pattern long from current price up to $31.62DBVT is forming a nice fallen angel formation. It had a nice rally & now pulled back to moving average. We think it will continue upward from here.
* Trade Criteria *
Date First Found- November 21, 2017
Pattern/Why- Fallen angel
Entry Target Criteria- Present price ($24.43)
Exit Target Criteri
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.